Belgium's Precirix Beats Biotech Blues With Major Cash Boost
Radiopharmaceuticals Specialist Raises €80m
Despite the sector's woes, strong companies that generate strong patient data based on solid science have a promising future, Precirix CEO Ruth Devenyns tells Scrip.
You may also be interested in...
RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.
Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge.
Although Bayer's radiopharmaceutical for prostate cancer Xofigo has proved a commercial disappointment, the Leverkusen-headquartered firm is keen to advance its pipeline of targeted alpha therapies, snapping up Noria and its subsidiary PSMA Therapeutics.